TY - JOUR
T1 - Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial
T2 - Three -years follow- up of a placebo-controlled trial
AU - Rusman, T.
AU - van der Weijden, M. A. C.
AU - Nurmohamed, M. T.
AU - van Denderen, C. J.
AU - Landewé, R. B. M.
AU - Bet, P. M.
AU - Bijl, C. MA van der
AU - van der Laken, C. J.
AU - van der Horst-Bruinsma, I. E.
AU - Bijl, Cma van der
N1 - Funding Information: This work was supported by an unrestricted financial grant from Pfizer and ReumaNederland. Funding Information: The authors have declared the following disclosures. MT Nurmohamed: received consulting fees from AbbVie, Celgene, Celltrion, Eli Lilly, Janssen, and Sanofi, speaker’s fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Roche, and Sanofi, and research funding from AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, MSD, Mundipharma, Novartis, Pfizer, Roche, and Sanofi. RBM Landewé: received honoraria for lectures and consultancies from AbbVie, Pfizer, Eli-Lilly, Novartis, Gilead, Galapagos, UCB, and Jansen; owns Rheumatology Consultancy BV, a company that provides read services for academic partners and pharmaceutical industries. IE van der Horst-Bruinsma: has received consulting fees, research or institutional support and educational grants from: AbbVie, Eli-Lilly, Bristol Myers-Squibb, MSD, Novartis, Pfizer, and UCB Pharma. T Rusman, MAC van der Weijden, CJ van Denderen, PM Bet, CMA van der Bijl, and CJ van der Laken: none in relation to this study. Publisher Copyright: © 2022 Scandinavian Journal of Rheumatology Foundation.
PY - 2022/5/11
Y1 - 2022/5/11
N2 - Objective: To study the long-term effect of 16 weeks of etanercept treatment on disease activity and radiographic changes in patients with suspected non-radiographic axial spondyloarthritis (nr-axSpA). Method: Eighty patients with inflammatory back pain and suspected nr-axSpA, with a Bath Ankylosing Disease Activity Index (BASDAI) ≥ 4, received etanercept (n = 40) 25 mg twice weekly or placebo (n = 40) for 16 weeks. They were followed without treatment restrictions after 24 weeks, for up to 3 years. Comparisons were made between patients who received etanercept or placebo in the first period, and changes in BASDAI, Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Metrology Index (BASMI), function, and radiographic changes in the spine [according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)] and sacroiliac joints (Bath Ankylosing Spondylitis Radiology Index (BASRI). Results: After 3 years of follow-up, 84% of the patients were diagnosed with SpA, predominantly axSpA. Biological treatment was started after 24 weeks in 30% of patients. Disease activity scores after 3 years did not reveal significant differences between the initial randomization groups in mean BASDAI scores (mean difference 0.9, 95% CI −1.1;0.7, p = 0.6) and ASDAS (mean ASDAS 0.3, 95% CI 0.6;3.1, p = 0.5). BASMI and function scores remained stable over 3 years. No differences in radiographic changes of the sacroiliac joints or spine were observed over 3 years between the two groups. Conclusion: A short course of etanercept in patients with suspected nr-axSpA did not affect disease activity, the chance of biological treatment, or radiographic progression after 3 years of follow-up.
AB - Objective: To study the long-term effect of 16 weeks of etanercept treatment on disease activity and radiographic changes in patients with suspected non-radiographic axial spondyloarthritis (nr-axSpA). Method: Eighty patients with inflammatory back pain and suspected nr-axSpA, with a Bath Ankylosing Disease Activity Index (BASDAI) ≥ 4, received etanercept (n = 40) 25 mg twice weekly or placebo (n = 40) for 16 weeks. They were followed without treatment restrictions after 24 weeks, for up to 3 years. Comparisons were made between patients who received etanercept or placebo in the first period, and changes in BASDAI, Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Metrology Index (BASMI), function, and radiographic changes in the spine [according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)] and sacroiliac joints (Bath Ankylosing Spondylitis Radiology Index (BASRI). Results: After 3 years of follow-up, 84% of the patients were diagnosed with SpA, predominantly axSpA. Biological treatment was started after 24 weeks in 30% of patients. Disease activity scores after 3 years did not reveal significant differences between the initial randomization groups in mean BASDAI scores (mean difference 0.9, 95% CI −1.1;0.7, p = 0.6) and ASDAS (mean ASDAS 0.3, 95% CI 0.6;3.1, p = 0.5). BASMI and function scores remained stable over 3 years. No differences in radiographic changes of the sacroiliac joints or spine were observed over 3 years between the two groups. Conclusion: A short course of etanercept in patients with suspected nr-axSpA did not affect disease activity, the chance of biological treatment, or radiographic progression after 3 years of follow-up.
UR - http://www.scopus.com/inward/record.url?scp=85130265610&partnerID=8YFLogxK
U2 - https://doi.org/10.1080/03009742.2022.2050502
DO - https://doi.org/10.1080/03009742.2022.2050502
M3 - Article
C2 - 35543102
SN - 0300-9742
SP - 1
EP - 5
JO - Scandinavian Journal of Rheumatology
JF - Scandinavian Journal of Rheumatology
ER -